Novartis will eliminate 450 U.S. jobs over the next two years during the gradual closure of its generic drug manufacturing plant in Broomfield, Colo., reports Reuters.
Novartis will close the plant and transfer some operations to a Sandoz facility in North Carolina by late 2019. Novartis is Sandoz's parent company.
The drug company will also discontinue or divest certain drug products to stay competitive in the U.S. drug market.
"The products that are being discontinued are oral generics that treat a variety of conditions in cardiology, central nervous system, endocrinology, respiratory and pain," a Novartis spokesman told Reuters Thursday.
More articles on supply chain:
Survey: 5 attributes providers want when purchasing medical devices
Study: Cancer drug costs increase 25% in 8 years
UnitedHealth not concerned by possibility of Amazon entering drug business